Tumours develop through an evolutionary process that usually spans multiple decades. During the expansion of cell populations, intratumoural heterogeneity arises as a natural consequence of imperfect DNA replication [1] [2] [3] [4] . Whenever a cell divides, a few mutations across the whole genome are acquired 5 . In a tumour composed of billions of cells, every conceivable point mutation is expected to be present in at least a few cells. At the genetic level, not only is every cancer type different but also every tumour of the same type and every cell of the same tumour are different. This extensive heterogeneity has been considered a major barrier to drug development and long-term disease control [6] [7] [8] [9] [10] [11] . However, the success (even if short-lived) of several forms of targeted therapies suggests that intratumoural heterogeneity does not preclude initial therapeutic response. For example, in patients with metastases -who represent the majority of patients treated with therapeutic agents -it would be difficult to observe an objective response if some metastatic lesions did not harbour the targeted driver-gene mutation in the vast majority of their cells 7 . How can the successful responses to targeted therapies be reconciled with the intratumoural heterogeneity that has been observed in next-generation sequencing studies?
In this Analysis article, we review the different forms of genetic tumour heterogeneity and re-evaluate sequencing data in the literature with particular regard to the clinical relevance of intratumoural heterogeneity. As a result of the different forms of tumour heterogeneity and the recent focus on subclonal heterogeneity, some discrepancies have arisen between the interpretations of observed heterogeneity and its clinical implications 2, 12 . Other discrepancies arise from loose distinctions between functional driver-gene mutations and passenger mutations, because not every mutation within a bona fide driver gene actually drives tumorigenesis 2, [13] [14] [15] . When these factors are taken into account, the sequencing data are in harmony with clinical experience. Homogeneity of true driver-gene mutations emerges as the rule rather than the exception in treatment-naive cancers.
Mutated driver genes in tumour evolution
Before we delve into a quantitative description of tumour heterogeneity at the genetic level, we review some of the basic principles underlying the genetic determinants of cancer. Solid tumours typically require alterations of three driver genes to convert a normal cell into a cancer cell 2, [16] [17] [18] [19] [20] [21] , although this number can vary
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Mutations present in only a subset of the tumour's cells. They are sometimes described as 'branched' because they occur on a branch of the tree when the evolutionary trajectory of the tumour is assessed. 2, 7, 8 , Martin A. Nowak 3, 9, 10 * and Bert Vogelstein 2, 7, 8, 11 * Abstract | Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication. Any two randomly selected cells, whether normal or cancerous, are therefore genetically different. Here, we review the different forms of genetic heterogeneity in cancer and re-analyse the extent of genetic heterogeneity within seven types of untreated epithelial cancers, with particular regard to its clinical relevance. We find that the homogeneity of predicted functional mutations in driver genes is the rule rather than the exception. In primary tumours with multiple samples, 97% of driver-gene mutations in 38 patients were homogeneous. Moreover, among metastases from the same primary tumour, 100% of the driver mutations in 17 patients were homogeneous. With a single biopsy of a primary tumour in 14 patients, the likelihood of missing a functional driver-gene mutation that was present in all metastases was 2.6%. Furthermore, all functional driver-gene mutations detected in these 14 primary tumours were present among all their metastases. Finally , we found that individual metastatic lesions responded concordantly to targeted therapies in 91% of 44 patients. These analyses indicate that the cells within the primary tumours that gave rise to metastases are genetically homogeneous with respect to functional driver-gene mutations, and we suggest that future efforts to develop combination therapies have the potential to be curative. among cancer types and individual patients. Each of these alterations promotes tumorigenesis by providing a selective growth advantage to the cells within their microenvironment. In other words, driver-gene mutations result in an increase in cell division or a decrease in cell death, resulting in a net cell gain overall. Relatively small changes in the cell birth rate, b, or in the death rate, d, can dramatically alter the net growth rate, given by r = b − d (refs 22-27 ). For example, assume that a tumour grows exponentially, with a volume doubling time of 150 days 28 . The growth rate is then r = ln(2)/150 ≈ 0.5% per day. If the cells within the tumour divide every 4 days 5, 29 , then b = 1/4 = 0.25 per day, and the death rate is d = b − r = 0.245 per day according to the formula given above. Suppose that a driver-gene mutation then occurs in one cell of this tumour. A driver-gene mutation causes an increase in the birth rate of on average 0.4% 22 , although some driver-gene mutations can confer much stronger or weaker selective advantages 30, 31 . A typical new birth rate is then b' = b(1 + 0.004) = 0.251 per day. If the death rate is unchanged, then the new growth rate of this cell is r' = b' − d = 0.6% per day. The new mutation therefore increases the net growth rate by 20% per day (= 0.6%/0.5%). The number of these mutated cells will then double every ~120 days (= ln(2)/0.006), as compared with the 150 days of the cells without this additional driver-gene mutation. Over many months to years, this difference is sufficient for cells with this driver-gene mutation to progressively outgrow the cells without this additional mutation in the tumour 22, [32] [33] [34] [35] . Driver genes can be classified into well-defined signalling pathways, and their effects depend on the tissue origin of the cells. A few dozens of driver genes are recurrently mutated across many cancer types, but most driver genes are recurrently mutated only in a few tissues and cancer types 36, 37 . The functional consequences of mutated driver genes complement each other, resulting in patterns of co-occurrence and mutual exclusivity among driver-gene mutations 37, 38 . In the case of oncogenes, a single missense mutation generally represents the genetic alteration responsible for activating it. In the case of tumour suppressor genes, inactivation typically requires two separate mutations. Preliminary evidence suggests that one of these mutations is usually intragenic (producing a stop codon, for example), while the other is often a large deletion that inactivates the other allele 39, 40 . It is important to note that some driver genes (for example, NOTCH1 or CDH1) can act as oncogenes in one cancer type but as tumour suppressor genes in other cancer types 2, 36 , reflecting the different signalling circuitries that define organogenesis; as such, not all driver genes follow the typical mutational patterns.
In the case of three mutated driver genes, the first driver-gene mutation usually allows the formation of a small clonal expansion, creating a benign lesion 18, 41, 42 . These lesions typically grow to a size of a few million cells and are usually undetectable clinically. The second driver-gene mutation results in a second wave of local clonal expansion, often leading to a clinically detectable, although still benign, tumour 20, [43] [44] [45] . The third mutation endows the tumour cell not only with a further selective growth advantage but also with the ability to expand in its environment by invading through the basement membrane 20, 45 , thereby defining malignancy (that is, cancer). Furthermore, advanced tumours typically contain frequent gains and losses of focal genomic regions, chromosome arms and whole chromosomes 40, 46, 47 . Depending on the cancer type, whole-genome duplication occurs in 10-80% of cancers, which could lead to subsequent chromosomal alterations 39, 48 . To date, it has been impossible to determine whether the rate of chromosome gains and losses (chromosome instability) increases during tumour progression. However, a new approach employing organoids should make this determination possible in the future 49 . Despite intense efforts, no genetic alterations have been identified that unambiguously endow the cell with the ability to metastasize 50 . The process of metastasis seems stochastic; once a cancer has developed (that is, once a tumour has acquired invasive growth capability), it may only be a matter of time before a cell invades a vessel and seeds a distant metastasis 14 . Although three driver-gene mutations appear to be sufficient for the development of most malignant solid tumours, more than three mutated driver genes can be observed in tumours, because the evolutionary process never stops. These additional mutations can be clonal, but are more likely to be subclonal, compared with the mutations driving the disease.
Heterogeneity among driver-gene mutations in benign tumours and expanded clones occurs frequently [19] [20] [21] 45, [51] [52] [53] . However, this heterogeneity can essentially be erased in the primary tumour by a mutation that endows a strong growth advantage 33 (for example, the last driver-gene mutation in the chain resulting in the advent of malignancy). In the parlance of population genetics, such a mutation results in a clonal sweep; the vast majority of the cells within the tumour descend from this mutant cell, which outcompeted other clones in the developing tumour ( fig. 1 ).
Relatively few mutations result in a gain or loss of function of a driver gene to confer a selective growth advantage. We define these driver-gene mutations as functional because they increase the rate of cell division or decrease the rate of cell death. Just because a mutation occurs in a driver gene does not mean that it drives tumorigenesis. Mutations in driver genes that are not functional should be considered passenger mutations because of their effectively neutral consequences on selection 14, 24, 36, 54 . With sufficient deep sequencing, essentially every possible point mutation in every gene will be observed. Many candidate driver-gene lists already contain more than 500 genes 55, 56 , and drivergene mutations are becoming increasingly likely to be false positives. Each mutation in a driver gene needs to be carefully assessed before functional consequences should be indicated. In this Analysis article, we have attempted to rigorously distinguish mutations that are likely to be functional from those that are not.
A final and often unappreciated point about genetic heterogeneity is that it is not confined to tumours. Any two randomly selected normal cells from a healthy adult contain hundreds to thousands of genetic alterations that distinguish the two cells 3, [57] [58] [59] [60] [61] . One can precisely quantify heterogeneity and evolutionary relationships through various metrics, such as the simpson index, the shannon index or the Jaccard similarity coefficient 27, [62] [63] [64] [65] [66] [67] . Applied both to normal and cancer cells, these metrics reveal that cancer cells are more similar to each other than normal cells are to each other. For example, the fraction of distinct genetic alterations between any two random cancer cells from a single cancer is much smaller than that between any two random normal cells from a normal organ 57, 65 . The reduced heterogeneity in cancer cells is a consequence of the clonal sweeps described above, which wipes out all previous heterogeneity among the other clones ( fig. 1) . Viewed in such a quantitative context and in comparison with normal cells, the extent of intratumoural genetic heterogeneity does not emerge as a distinctive feature of cancer. Nevertheless, and independent of the degree of heterogeneity, the key questions addressed in this article remain the same: in which situations are genetic heterogeneity clinically important, and why.
Forms of tumour heterogeneity
Genetic differences between the cancers of two patients, each with a different tumour type (intertype heterogeneity) are well known (for example, mutations present in prostate cancer versus pancreatic cancer). Even cancers of the same type in two different individuals are genetically very different and may share very few or no somatic mutations (intratype heterogeneity). These differences are the basis for precision medicine: patients are treated with drugs that target the genetic alterations that are present in their particular tumour. This contrasts with conventional chemotherapeutics, in which all patients with a given tumour type are treated identically. Perhaps the epitome of personalized medicine is illustrated by the 'tumour type-agnostic' approval of immune checkpoint inhibitors for cancers 68 . The drug pembrolizumab is now recommended for the treatment of patients whose tumours are mismatch-repair deficient, regardless of the tumour type. A similar tumour type-agnostic indication for patients with tumours bearing TRK mutations was recently approved 69 .
In this Analysis article, we focus on three forms of heterogeneity that affect the same cancer in a single individual 2, 70 : intraprimary heterogeneity refers to the genetic heterogeneity between two cells of the same primary tumour; intermetastatic heterogeneity refers to the genetic heterogeneity between the cells that seed different metastases; and intrametastatic heterogeneity refers to the genetic heterogeneity between two cells of the same metastasis ( fig. 2 ).
Intraprimary heterogeneity
Intraprimary heterogeneity can directly affect patient outcomes only when the primary tumour cannot be completely excised. As is depicted in fig. 3 , in ~57% of all newly diagnosed cancers in the United States, the primary tumour is surgically resectable. For selected common solid cancers (representing 81% of all new cancer cases in the United States), ~70% of the primary tumours New driver-gene mutations in another subclone (grey) may be acquired during the growth of the lesion.
Simpson index
An index denoting the probability that two randomly chosen cancer cells would belong to the same subclone.
Shannon index
An index describing the uncertainty of predicting the subclone of a randomly chosen cancer cell.
Jaccard similarity coefficient
A measure defined as the ratio of the number of shared mutations to all mutations in two samples.
are surgically resectable 71 , and intraprimary heterogeneity is clinically irrelevant. Nonetheless, intraprimary heterogeneity can sometimes provide important prognostic information 55, 62, 67, 72 . Moreover, when the primary tumour cannot be completely resected, such as is mostly the case in glioblastomas 73 , intraprimary heterogeneity among driver genes can limit the response to therapies that target such driver genes. Such driver heterogeneity explains, for example, why agents that target epidermal growth factor receptor (EGFR) variants have not achieved notable clinical success in glioblastomas; not all cells within most glioblastomas contain this variant 74 . Intraprimary heterogeneity can be assessed through multi-region or single-cell sequencing of primary tumours. Several studies of this sort have revealed driver-gene mutations present only in a subset of the evaluated regions of some tumours [75] [76] [77] [78] [79] [80] [81] [82] . Some of this hetero geneity can be explained by sequencing noise, low neoplastic cell content or low sequencing depth in individual samples [82] [83] [84] [85] . For example, if the depth of sequencing for a specific genomic position is only n = 10 reads, and the neoplastic content of the tumour DNA used for sequencing is 50%, then the probability of completely missing that mutation (k = 0) when it occurs in 100% of the cancer cells is
(assuming that one of two alleles in the tumour cells is mutated, f = 0.5/2). The probability of missing at least one of three such mutations is
, if it is assumed that the mutation needs to be observed twice (k < 2) to ensure that it is real rather than an artefact of sequencing. Multi-sample analysis accentuates this problem, because the probability that sequencing depth or neoplastic cell content will be low in at least one sample strongly increases with the number of samples analysed 24 . Most sequencing data analysis methods have been optimized for single-sample analysis, and few methods have been described to minimize artefacts in the context of multi-sample analysis 83, 86 . Some of the newer methods to control for multi-sample analysis artefacts have been applied to the sequencing data described in this study (see the Supplementary Methods).
Minimal functional consequences of subclonal drivergene mutations. Intraprimary heterogeneity is conferred by subclonal mutations. But are the subclonal mutations that occur in driver genes functional and crucial to cancer progression? As we noted above, just because a mutation occurs in a driver gene does not mean that the particular mutation actually drives tumorigenesis. To address this question, we re-analysed data from 38 untreated primary epithelial tumours derived from 6 cancer types in which multi-region sequencing had been performed ( 83 (Supplementary Methods). Mutations were classified as absent if their 'absent probability' was at least 80%. Mutations that were present in at least one sample but not in all samples were classified as subclonal. Ambiguous mutations that did not reach these present or absent probability thresholds in all samples of a patient were excluded from the analysis, to minimize the effects of low sequencing depth or low neoplastic cell content. We thereby identified 19 subclonal, nonsynonymous mutations within the 299 driver genes listed in The Cancer Genome Atlas (TCGA) consensus list 36 ( fig. 4a ; Supplementary Table 1 ). The number of subclonal mutations was considerably less than the number of clonal mutations (19 subclonal versus 143 clonal in the same 38 cancers).
To determine whether these 19 subclonal mutations were likely to be functional, we pooled information from various databases and used bioinformatic methods to create a two-phase algorithm, called Likely Functional Driver (LiFD; Supplementary Methods) 90 . However, additional driver-gene mutations can be acquired during the growth process of the metastatic lesion. Whether intrametastatic heterogeneity can arise from the dissemination of new clones from one metastatic lesion to another is the subject of ongoing research 81, 142, 143 .
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In the first phase of LiFD, mutations that are annotated in OncoKB 91 , the catalogue of validated oncogenic mutations in the Cancer Genome Interpreter (CGI) 13 , are known cancer hotspots 92 or are present at least four times in the Catalogue of Somatic Mutations in Cancer (COSMIC) 93 were predicted to be functional. If a mutation was not annotated as functional in the first phase, we used Cancer-Specific High-Throughput Annotation of Somatic Mutations (CHASMplus 15, 94 ), Functional Analysis through Hidden Markov Models (FATHMM cancer driver annotation (CanDrA 96 ), CGI 13 and variant effect predictor (VEP 97 ) to predict the functional consequences of this mutation in the second phase of LiFD. If the majority (>50%) of the methods that produced a result predicted functionality, we classified the mutation as likely functional (Supplementary Methods; Supplementary Fig. 1 ). This method was lenient, in that it allowed mutations scored as significant, as judged by only a subset of the tools, to be considered functional by LiFD.
Through LiFD, we found that clonal mutations in putative driver genes were significantly more likely to have functional consequences than subclonal driver-gene mutations in the same tumours ( fig. 4a ; Supplementary Table 1) . Only 2 (11%) of the 19 subclonal mutations, compared with 77 (54%) of the 143 clonal mutations, were predicted to be functional (P < 0.001, two-sided Fisher's exact test; fig. 4a ). The two likely functional subclonal driver-gene mutations occurred in PTEN in the same patient, one in each of two regions of the breast cancer. When evaluated at the individual tumour level, 97% (37 out of 38) of the tumours evaluated had no functional subclonal driver-gene mutations (fig. 4) . On average, we found 2.1 distinct likely functional driver-gene mutations across all sequenced regions per primary tumour.
Survival analysis of patients with subclonal driver-gene mutations. Another clinically important question is whether patients whose tumours have subclonal mutations in driver genes, and are thus heterogeneous with respect to driver-gene mutations, have a worse prognosis than patients without such heterogeneity 62, 72, 77, [98] [99] [100] . To address this question, we re-analysed data from 100 early-stage non-small-cell lung cancers in which 62 subjects were reported to have at least 1 subclonal driver-gene mutation 55 (either a point mutation or short insertion or deletion). We did not find a statistically significant difference in disease-free survival between patients who exhibited subclonal driver-gene mutations (n = 62) and those who did not (n = 38) based on the originally reported heterogeneity and driver classification ( fig. 5a ). When the heterogeneity classification and the LiFD classification described above were used (Supplementary Methods), the number of cancers harbouring subclonal driver-gene mutations decreased from 62 to 32. Nevertheless, no significant difference in patient outcomes was observed (fig. 5b) . Although it would be reasonable to expect that tumours that had acquired additional driver-gene mutations would be more aggressive, allowing escape from host control and conferring worse survival, this was not the . a | Driver-gene mutations present in all samples from a single primary tumour were more frequently predicted to be functional than those present in only a subset of the samples from a primary tumour (54% versus 11%, P < 0.001). The fraction of subclonal functional driver-gene mutations (11%) was not significantly different from the fraction of clonal or subclonal functional passenger-gene mutations in the same tumour (3.3% and 2.3%, respectively). b | Mutations in driver genes that were present among all metastasis samples of a subject were more frequently predicted to be functional than those present only in a subset of the metastasis samples (65% and 0%, respectively ; P < 0.001). The fraction of subclonal functional driver-gene mutations (0%) was not significantly different from the fractions of clonal and subclonal functional passenger-gene mutations in the same samples (4.1% and 6.6%, respectively). c | On average, 69% and 66% of the mutations per patient were clonal (homogeneous) among primary tumour samples and among metastases, respectively. Mutations in putative driver genes were significantly more homogeneous among primary tumour samples (90%, P < 0.001) and among metastases (84%, P < 0.0048) than mutations in all genes (sum of passenger genes and driver genes). Likely functional driver-gene mutations were even more homogeneous, both among primary tumour samples (98%, P < 0.0042) and among metastases (100%, P < 0.0018), than other categories of mutations. Two-sided Fisher's exact tests were used in parts a and b. Two-sided Wilcoxon rank-sum tests were used in part c. The black bars denote 90% confidence intervals. The numbers above each bar denote the number of predicted functional variants over the total number of variants in each group. **P < 0.01; ***P < 0.001.
case in this study. We again found that clonal mutations in driver genes were significantly more likely to be functional than subclonal mutations (33% versus 20%; P < 0.001, two-sided Fisher's exact test), although the high mutation rate in lung cancers complicates the driver functionality prediction.
Single biopsies generally provide adequate information for precision medicine. Intraprimary tumour heterogeneity also informs the number of biopsies required for choosing the optimal targeted therapies for metastatic lesions. For example, if only a single region of a primary tumour is biopsied, what would be the probability of selecting a functional (and perhaps targetable) drivergene mutation that was not present in all metastases? Conversely, what would be the probability of missing a functional driver-gene mutation that was present in all metastases if only a single biopsy was used for sequencing analysis? To address these questions, we re-analysed data from 14 treatment-naive subjects (5 pancreatic, 3 colorectal, 3 endometrial, 2 breast and 1 gastric cancers), in whom at least 1 sample of the primary tumour and at least 2 distinct metastases were sequenced 14 . First, any detected functional driver-gene mutations present in a primary tumour biopsy were also present among all metastases of that patient. Second, we found that the proportion of functional driver-gene mutations present in all metastases but missing from a primary tumour biopsy was on average 2.6% (Supplementary Methods; Supplementary Table 2 ). These data support the conclusion that, in most patients, a single biopsy of a primary tumour captures the information necessary for therapeutic choices about the treatment of extant or presumptive metastases. Because untreated samples of the primary tumour and of multiple metastases are rarely available, these analysis results are based on a relatively small cohort, representing only five cancer types. Further research will be required to determine the clinical scenarios in which multiple rather than single biopsies are advantageous. For example, when lesions are multi-focal, such as in the oesophagus, evaluation of biopsies from several sites clearly provides useful information 55, 67, 72, 101 .
Intermetastatic heterogeneity
Intermetastatic heterogeneity is the most important form of heterogeneity for patients with primary tumours that can be completely excised 2, 14, 102 . Intermetastatic heterogeneity of driver-gene mutations determines whether all lesions have the capacity to respond to a given targeted therapeutic agent. If even a single lesion lacks the drivergene mutation being targeted, and therefore continues to grow following the initiation of therapy, it is much less likely that an objective response will be observed than if all lesions harbour the mutation 103 . Most studies of intratumoural heterogeneity have focused on primary tumours, although metastases are responsible for most cancer-related deaths. Moreover, intermetastatic heterogeneity provides a uniquely informative view of intraprimary heterogeneity. If intraprimary heterogeneity was important for the treatment response of metastatic disease, some metastases would be derived from the subclones in the primary tumour that define this heterogeneity. In previous studies addressing this issue, patients had often been treated with toxic or mutagenic agents, which complicate the inter pretation of mutations observed in metastases. . a | No statistically significant difference in disease-free survival is apparent between patients who harboured subclonal driver mutations (n = 62) and those who did not harbour any subclonal driver-gene mutations (n = 38), according to the originally provided driver and heterogeneity classification. The shaded areas denote 90% confidence intervals. The hazard ratio of subjects with subclonal driver-gene mutations was 0.51 (95% CI 0.24-1.1; P = 0.088, likelihood ratio test). b | When the Likely Functional Driver (LiFD) algorithm for identifying functional driver-gene mutations was applied, the number of patients who harboured subclonal drivergene mutations was 32, and the number of patients who did not harbour any functional driver-gene mutations was 68. No statistically significant difference in disease-free survival was observed between patients who harboured subclonal functional driver-gene mutations and those who did not harbour subclonal functional driver-gene mutations. The hazard ratio of subjects with subclonal functional driver-gene mutations was 1.4 (95% CI 0.61-3.0; P = 0.46, likelihood ratio test). In part b, a different heterogeneity classification was performed than in part a (Supplementary Methods).
Nature reviews | CanCer
We therefore surveyed the literature for patients in which at least two distant treatment-naive metastases underwent genome-wide or exome-wide sequencing 14 . Across all cancer types, and among tens of thousands of patients in whom genome-wide sequencing was performed, only 17 subjects were found to fulfil these requirements (6 pancreatic 65 Methods) . Using the LiFD classification framework, we found that 65% (44 out of 68) of all clonal nonsynonymous mutations in driver genes were predicted to be functional, while no (0 out of 14) subclonal mutations were predicted to be functional ( fig. 4b; Supplementary  Table 3 ). Hence, all of the predicted functional drivergene mutations were present in all metastatic lesions of individual patients (fig. 4c) . The fraction of subclonal driver-gene mutations predicted to be functional (0%) was not significantly different from the fractions of clonal and subclonal passenger-gene mutations predicted to be functional (4.1% (26 out of 638) and 6.6% (28 out of 426), respectively). We repeated this functional analysis with a more expansive driver-gene list 107 and obtained similar results (Supplementary Fig. 2 ; Supplementary Methods).
For previously treated metastases, varying degrees of intermetastatic heterogeneity of driver-gene mutations have been reported within and across cancer types 65, 75, 102, [108] [109] [110] [111] [112] . This is not unexpected because therapies create selective bottlenecks that unmask additional mutations. Which of these additional mutations in driver or passenger genes actively contribute to progression and resistance is often unclear, particularly when no functional analysis was performed. Moreover, the selective bottleneck enforced by a therapeutic agent can be very different from the selective bottlenecks operating during cancer initiation and progression: a potent driver mutation of cancer initiation may not contribute to resistance, and a potent resistance mutation may not drive tumorigenesis. Some of the additionally observed driver-gene mutations can be explained by their role in conferring resistance. For example, KRAS mutations following treatment with EGFR inhibitors, loss of PTEN following treatment with PI3Kα inhibitors, or fibroblast growth factor receptor 2 (FGFR2) mutations following treatment of patients with cholangiocarcinoma with FGFR inhibitors 7, 10, 28, [113] [114] [115] [116] [117] . The mutations that confer resistance to targeted agents such as these are lesionspecific and can differ considerably among the metastases of a single patient. This type of intrametastatic heterogeneity is very important for selecting second-line therapies. However, it is typically not relevant for selecting the initial therapies for newly diagnosed patients, because it is usually only present in a tiny fraction of metastatic cells prior to therapy 9, 24 . Clinical correlates of intermetastatic heterogeneity. The success of targeted therapies for most cancers is dependent on the homogeneity of the targeted driver-gene mutations among metastases. At present, nearly all targeted therapies are based on oncogene alterations. Tumour suppressor gene alterations cannot yet be targeted by US Food and Drug Administration (FDA)-approved drugs because it is challenging to restore the function of an inactivated protein. The conclusions described above, based on genome-wide sequencing of metastatic lesions in untreated patients, are strongly supported by sequencing studies of individual oncogenes in metastases from the same patients. For example, it has been shown that mutations in KRAS, NRAS, BRAF and PIK3CA (which encodes a catalytic subunit of PI3K) are nearly always concordant across all metastatic lesions in patients with colorectal cancer 118, 119 . The same EGFR mutations are similarly almost always found in all meta static lesions in patients with lung adenocarcinoma 120 , and the same BRAF and NRAS mutations are found in the metastatic lesions of patients with melanomas 121, 122 . Perhaps most importantly, are the actual responses observed in patients treated with targeted therapies consistent with the predicted homogeneity among driver genes determined in this analysis? Very few published studies provide detailed data on the response of individual lesions to targeted therapies. In general, most studies report only the response data required to meet the response evaluation criteria in solid tumours (RECIST) that is, whether the sum of the diameters of all measured lesions decreases or increases 103 . An objective response is reported if the sum of those diameters decreases by more than 30%, and tumour progression is reported if the sum increases by more than 20%. However, we gathered data from two clinical trials that more directly addressed the question considered here, as a proof of concept; that is, if one metastatic lesion responds to a targeted therapy, do all index metastatic lesions respond too, or do some lesions continue to grow?
In the first of the two trials, 33 patients with melanoma and at least 2 index lesions were treated with targeted therapy 123, 124 (the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib, or the BRAF inhibitor vemurafenib plus the MEK inhibitor cobimetinib). All patients had a BRAF V600E mutation in their primary tumours. Of these 33 patients, a decrease of ≥30% in diameter of at least 1 index lesion was observed in 27 patients ( fig. 6a; Supplementary Table 4) . We then determined how often one of the other index lesions in these 27 patients grew during the initial treatment period, generally 8-16 weeks and prior to the emergence of resistance. We found that in 23 of the 27 patients, none of the other index lesions grew by ≥10% (representative examples are in fig. 6b ).
In the second trial, 11 patients with metastatic thyroid cancers were treated with pazopanib (a vascular endothelial growth factor receptor (VEGFR), plateletderived growth factor receptor (PDGFR) and RAF inhibitor) and trametinib 125 . Of these 11 patients, a decrease of ≥30% in diameter of at least 1 index lesion was observed in 8 patients ( fig. 6c ; Supplementary Table 5) . In all 8 patients, none of the other index lesions grew by ≥10% during the first 6 months after the start of therapy or until the end of treatment (whichever occurred first).
The conclusions from both trials are therefore similar. When an objective tumour response from a targeted therapy is observed in one metastatic lesion, it is common (89% of 35 patients) for all lesions in that patient to respond to the therapy. If we include cases in which no lesion achieved an objective response, similar
Selective bottlenecks
The scenario in which a decrease of the tumour size (for example, due to therapy) leads to a decrease in genetic diversity and an increase in the prevalence of some subclones in the tumour.
Response evaluation criteria in solid tumours
(reCisT). A standardized measure of solid tumour response to a therapy.
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responses (regression or growth, sometimes mixed with stable diameters) of all index lesions were observed in 91% (40 out of 44) of the patients. Note that this does not mean that all index lesions respond in an identical manner. In some cases, all lesions regressed to the same extent ( fig. 6b) . In other cases, the timing and degree of response varied. The timing and degree of the response is dependent on a host of factors other than the presence of the targeted driver-gene mutation in the metastatic lesion. In particular, the timing and extent of a response depend on the vascularity in each tumour because this determines the dose actually delivered to the lesion 126, 127 .
The microenvironment can also impact drug delivery, and local immunity might play a role 128 . Moreover, the degree of a response depends on the number of cells in the lesion that contain a mutation that can confer resistance (intrametastatic heterogeneity). These additional factors are currently beyond the control of the oncologist. But, unless all metastatic lesions contain the targeted mutation, a targeted therapy will usually not be very useful. Fortunately, these clinical results confirm the above-noted sequencing studies, which demonstrated, in all 17 patients evaluated (and in all 67 distinct metastases from those patients), that if one metastasis contained a predicted functional driver-gene mutation, all of the other metastases of the same patient contained the identical mutation.
Intrametastatic heterogeneity
Intrametastatic heterogeneity does not impact the initial response to therapy but is responsible for disease recurrence after a response 7, 9, 10, 115 . Such recurrences result from mutations present in a small fraction of the cells within each metastasis prior to treatment: the larger the lesion, the more likely that such resistant cells will exist 9 . Thus, treatment of relatively early meta static states -with conventional chemotherapeutic agents, targeted agents or immunotherapeutic drugs -is much more likely to be successful than treatment of bulky metastatic disease. Although we did not formally analyse intrametastatic heterogeneity here, a recent study of 2,520 metastases in which deep whole-genome sequencing was performed showed that 96% of all driver-gene point mutations were clonal (reported in a preprint 39 ). Similarly, 95% of driver-gene mutations were shared among the metastatic lesions of individual patients in a study of 100 T1  T3  T4  T6  T7  T8  T10  T11  T2  T5  T9   0  10 A lesion was considered to respond if it shrank by at least 30% in diameter ; a lesion was considered to grow if its diameter increased by at least 10%; and a lesion was considered to be stable if it did not grow by at least 10% or shrink by at least 30%. a | At least one lesion responded in 27 of 33 patients with melanoma 123, 124 . In 23 patients (pink humanoids), no lesion grew. In four patients (blue humanoids), one of the lesions grew while the others responded that is, a heterogeneous response was observed. In six patients (purple humanoids), no lesion responded. b | Examples of different types of responses to targeted therapy , taken from the patients shown in part a. All lesions responded in patient M37. One lesion responded less well than three other lesions in patient M40. None of the lesions responded in patient M29. One lesion responded, two lesions remained stable and a fourth lesion grew in patient M08. c | At least one lesion responded in 8 of 11 patients with thyroid cancer 125 . In eight patients (pink humanoids), no lesions grew. In three patients (purple humanoids), no lesion responded. Additional information about these patients' responses is provided in Supplementary Tables 4,5. In 91% (40 out of 44) of the patients analysed (with melanomas or thyroid cancers), all lesions responded similarly to targeted therapy.
Conclusions
The data and analyses described above lead to several important conclusions. First, tumours are heterogeneous, but the term heterogeneity needs to be used with caution and nuance, as normal cells are heterogeneous too. We show that the extent of intraprimary heterogeneity of functional driver-gene mutations is relatively small (mean of 2% across all patients analysed; fig. 4c ). We point out that, unless the primary tumour cannot be completely excised, the extent of this heterogeneity is of little clinical consequence. More importantly, from an oncologist's viewpoint, the extent of heterogeneity of functional driver-gene mutations among metastases of the same patient is minimal (fig. 4c) . Moreover, the sequencing data amassed in the literature are highly concordant with this clinical experience ( fig. 6 ).
Multi-region sequencing enables a more refined inference of the genealogy of tumours, offering key insights into the nature of the tumorigenic process 130, 131 . For example, such sequencing has allowed investigators to determine the time course of tumorigenesis, which is now acknowledged to typically take decades 5, 20, 29, 40 (a result also consistent with clinical experience). A particularly informative example of this principle was recently published: the first genetic alteration in kidney cancers occurs during early adulthood, decades prior to the onset of malignancy 132 . The growth of a primary tumour and its subclonal diversification occur long after the first genetic alterations, typically a few years to a decade before diagnosis 40, 132 . Multi-region sequencing is also critical to evaluating the potential of targeted therapies to be effective in cancers that cannot be surgically excised in their entirety, such as brain tumours, or to forecast the future evolutionary trajectory of a tumour 24, 25, 62, 133 ( fig. 3 ). But for tumours that can be completely excised, sequencing of a single region from the primary tumour is generally adequate to find the clonal mutations susceptible to targeted adjuvant therapies ( fig. 4 ; Supplementary Table 2) .
Our study has several limitations. One of them is that our analyses of heterogeneity were limited to intragenic mutations (single-base substitutions and small insertions and deletions). Other types of genetic alterations, as well as epigenetic alterations, undoubtedly play a role in tumorigenesis. For example, copy number alterations occur nearly ubiquitously in cancers and can confer selective advantages 134 . Unfortunately, the target genes selected for by such copy number alterations are notoriously difficult to identify 72, [134] [135] [136] [137] [138] . With dramatic changes in copy numbers (such as occurs with amplifications of ERBB2 or EGFR), the target gene can be identified. In the much more usual case of small changes in copy number (twofold to threefold imbalances), it is unknown whether such copy number changes reflect a single underlying culprit gene, the combined effect of many genes 132, 134, 136 or simply represent passenger alterations arising as a result of chromosomal instability 40, 46, 48 . Mutations in non-coding regions of the genome also play a role in certain cancers. Individual non-coding mutations that drive tumorigenesis are rarely recurrent, with a few exceptions, such as mutations in the telomerase reverse transcriptase (TERT) promoter 139, 140 . Moreover, as with copy number changes, it is currently very challenging to determine whether a given non-coding mutation is functional; tools such as those used here for predicting the effects on tumorigenesis of non-coding mutations are in development 140 . The same challenges apply to the thousands of epigenetic changes that occur in every cancer. Unless these epigenetic changes occur in the ~300 known recurrently mutated driver genes 2, 36, 107, 134, 141 , it is currently unfeasible to reliably discern which of them are likely to drive tumorigenesis -that is, to cause a selective growth advantage in the actual human tumour microenvironment in which they occur. Another limitation involves the difficulty of identifying functional genetic mutations. The LiFD classification framework combines the evidence of various databases and algorithms to minimize both false positives and false negatives, but it is still only predictive rather than definitive. Finally, these studies of untreated cancers with numerously sampled primary tumours and metastases by necessity involved only a small number of cases. As sequencing becomes routine in clinical and research studies, we expect it will be possible to extend our type of evaluation to many other cancer cases.
The analyses presented herein provide optimism for future combinations of adjuvant therapies following surgical excision of primary tumours. If intermetastatic heterogeneity in driver genes was routinely found, there would be little hope of achieving meaningful responses in most patients. We find that such heterogeneity is rare (fig. 4) , and this is compatible with the clinical success of targeted therapies in patients with metastatic disease (fig. 6 ). Although these individual targeted therapies are not curative because of evolving resistance within metastases (intrametastatic heterogeneity), there is no theoretical reason why combinations of targeted therapies could not be curative 10 . Indeed, it has been shown that treatment of metastases with just two drugs for which no single alteration can confer cross-resistance should, in theory, cure most cancers 9 . These results apply not only to those driver-gene mutations that are currently targeted but also to future targeted therapies -so such cures appear to be possible and eminently worthy of further pursuit.
